Access all of the content
touchIMMUNOLOGY meets Dr Pia Kvistborg at the Virtual 2020 ESMO Congress to discuss the presentation of her late-breaking abstract ‘The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01’ (LBA73) and initial findings from her recent study.
- How did your collaboration with Andrea Cossarizza on SARS-CoV-2 come about? (0:12)
- How have you applied cancer research technology to elucidate structural components of the SARS-CoV-2 virus? (1:04)
- Could you give us an overview of the aims and design of your recent study? (2:40)
- What were the main findings of your study? (4:48)
- What are the implications of these findings on vaccine design? (10:55)
Speaker Disclosure: Pia Kvistborg has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In COVID-19
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 […]
James Alexander, UEG Week 2022: Antibody and T-cell Response to the Third COVID-19 Vaccine Dose in Immunosuppressed Patients with Inflammatory Bowel Disease
The VIP study was a multicentre, prospective, case-control study, investigating whether immunosuppressive treatments reduced antibody and T-cell responses in patients with inflammatory bowel disease (IBD) after a third COVID-19 vaccine dose. In this touchIMMUNOLOGY interview, we speak with Dr. James Alexander (Imperial College London, London, UK) to discuss the aims, methodology and findings from the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!